Leadership Team
Together, we’re working to create a new generation of medicines to transform patients’ lives. We have an amazing team of people, with a deep understanding of targeted protein degradation science, who always want to bring out the best in others. It’s our values that set us apart.
Andrew Hirsch, MBA joined C4 Therapeutics in September 2020 as our President, Chief Executive Officer, and a member of our Board of Directors. Previously, Andrew was Chief Financial Officer and Head of Corporate Development at Agios Pharmaceuticals, Inc. Andrew has more than 25 years of experience in a range of strategic and operating roles in the biotechnology sector, previously serving as President and Chief Executive Officer of BIND Therapeutics, Inc. Prior to being named President and Chief Executive Officer, Andrew held several other leadership positions at BIND, including Chief Operating Officer and Chief Financial Officer. Before joining BIND, Andrew was Chief Financial Officer at Avila Therapeutics, Inc. from June 2011 until its acquisition by Celgene Corporation. From 2002 to 2011, Andrew held roles of increasing responsibility at Biogen Inc., including Vice President of Corporate Strategy and M&A and Program Executive for the Tecfidera development team. Since May 2017, Andrew has served on the Board of Directors of Editas Medicine, Inc. Andrew holds an MBA from the Tuck School at Dartmouth College and a B.A. in economics from the University of Pennsylvania.
Our team is strong because we utilize our cross-functional capabilities to collaborate and make decisions that advance our programs. We take the time to join as one to understand what is ahead and how we, as a collective, can find fundamentally different ways to treat patients through targeted protein degradation.
Kendra Adams joined C4 Therapeutics in November 2020 and has served as our Chief Financial Officer since September 2023. Between November 2020 and August 2023, Kendra served as our Senior Vice President of Communications and Investor Relations. Kendra has more than 25 years of experience in financial, operational and strategic planning, including more than two decades of experience in the biotechnology sector where she has developed investor relations programs focused on ensuring investors and external audiences understand the company’s financial position and capital allocation strategy to advance research and clinical pipelines. Previously, Kendra served as Vice President, Investor Relations and External Communications at Agios Pharmaceuticals where she held roles of increasing breadth and responsibility during her tenure. Earlier in her career, she served in investor relations roles of increasing responsibility at ARIAD Pharmaceuticals and Amgen. Kendra began her professional career at General Electric, where she participated in the company’s Financial Management Program. After GE, she joined KPMG LLP where she led consulting teams on a variety of financial and strategic matters. Kendra holds a B.A. in economics from Hamilton College.
We want more patients to benefit from next-generation therapies that precisely target their disease. The ambition that the C4T team holds for developing therapies that deliver transformative change for people who need it is at the core of our work every day.
Scott Boyle, Ph.D., MBA joined C4 Therapeutics in January 2022 as our Chief Business Officer. Previously, Scott was at Forma Therapeutics as Vice President, Business and Corporate Development. He has served clients in oncology and precision medicine at Boston Consulting Group (BCG) and built the business development function at Caris Life Sciences, where he held roles of increasing responsibility. Scott earned a Ph.D. in molecular biophysics and biochemistry from Yale University, an MBA from the Harvard Business School and a B.S. in biochemistry from Brigham Young University. He completed his postdoctoral fellowship at the Novartis Institute for Biomedical Research.
The promise of C4T’s platform and the unwavering dedication of our team is evident through our consistent delivery of highly catalytic, orally bioavailable degrader candidates across a wide range of target classes that have the potential to transform how medicine is practiced.
Paige Mahaney, Ph.D. joined C4 Therapeutics in October 2024 as our Chief Scientific Officer. Paige’s experience in pharmaceutical executive leadership spans more than 25 years, with multidisciplinary expertise in discovery research and development along with successfully building clinical portfolios across a wide range of disease indications and treatment modalities. Most recently, she served as senior vice president and corporate head of drug discovery at Exelixis, Inc., where she was responsible for the strategy and execution of the company’s drug discovery portfolio as well as advancing the early clinical pipeline. In just over three years at Exelixis, she built the discovery team and a state-of-the-art discovery platform while advancing multiple candidates toward investigational new drug applications and clinical trials, including a USP-1 inhibitor, XL309, and XL495, a PKMYT1 inhibitor. Prior to Exelixis, she spent over 10 years at Boehringer Ingelheim Pharmaceuticals, Inc. focused on pipeline expansion and discovery in positions including senior vice president, global head of biotherapeutics discovery and discovery research site head; senior vice president, head of small molecule discovery and discovery research site head; and vice president, head of small molecule discovery. While at Boehringer Ingelheim, Dr. Mahaney’s teams were responsible for delivering drug candidates to the company’s global clinical portfolio, including several investigational assets in oncology, immunology, cardiometabolic, inflammation and respiratory and orphan diseases, many of which have received FDA regulatory pathways including accelerated approval or breakthrough therapy designation. These include important contributions to the advancement of Spevigo®; a first-in-class IL36R blocking antibody for generalized pustular psoriasis; BI 764532, a first-in-class bi-specific T-Cell engager for neuroendocrine carcinomas and small cell lung carcinoma; avenciguat, a small molecule activator of soluble guanyl cyclase for systemic sclerosis; and vicadrostat, a small molecule inhibitor of aldosterone synthase for cardiorenal diseases. Earlier in her career, she held scientist roles in medicinal chemistry at Hoffman-La Roche, Inc. and Wyeth Pharmaceuticals. She received her Ph.D. in organic chemistry from the Massachusetts Institute of Technology (MIT) and her B.S. in chemistry from Guilford College.
Bringing new therapies to patients takes a team. Here at C4T, we have the opportunity to work with our colleagues, patients, caregivers and investigators to advance an exciting new scientific approach that has the potential to help patients live longer and healthier lives.
Leonard (Len) Reyno, M.D. joined C4 Therapeutics in July 2023 as our Chief Medical Officer. Previously, he served as President and Chief Medical Officer at Pionyr Immunotherapeutics. Len has close to 30 years of experience in oncology drug development experience, spanning from investigational new drug (IND) applications to Phase IV trials across pharmaceutical, biotech and academic settings. Prior to Pionyr Immunotherapies, Len was Executive Vice President and Chief Medical Officer at ORIC Pharmaceuticals. Previously, he spent a decade at Astellas Pharma in roles of increasing responsibility, most recently as Senior Vice President and Chief Medical Officer, Clinical Research and Development of Agensys, Inc., an affiliate of Astellas. Len has played pivotal roles in several drug approvals and launches, including Herceptin® for Her2+ breast cancer during his tenure at Genentech, Inc. and Taxotere® for the adjuvant treatment of breast cancer while at Aventis and Padcev® in metastatic bladder cancer. Len received his M.D. degree from McMaster University Medical School and a B.Sc. in Chemistry from Dalhousie University.
C4T has the right people, science and culture to make profound change in how we treat disease. We are built on teamwork and a commitment to working together with trust and respect to solve problems, and that enables the C4T team to have a positive impact on patients no matter what comes our way.
Jolie Siegel, J.D. joined C4 Therapeutics in July 2020 as our Chief Legal Officer and also serves as our Secretary. Previously, Jolie served as General Counsel and Secretary at Neon Therapeutics, an immune oncology company focused on developing personalized cancer vaccines and T cell therapies, a role she held through the sale of the company to BioNTech SE in May 2020. Prior to Neon, Jolie was the Senior Vice President, Deputy General Counsel and Assistant Secretary of Intralinks, a financial technology provider for the global banking, deal making and capital markets communities, a role she held through the sale of the company in 2017. Prior to her time in-house, she was a partner at Choate, Hall & Stewart LLP where she worked on corporate transactional, securities and general business matters, with an emphasis on private equity, venture capital and high-growth companies in life sciences and a range of other industries. Jolie started her legal career at Testa, Hurwitz & Thibeault, LLP, where she was a member of the business practice group. Jolie holds a J.D. from the University of Pennsylvania Law School and a B.A., cum laude, from the University of Pennsylvania.
We have great people at C4T, so collaboration across our diverse teams is fun. We all strive to advance our targeted protein degradation science, so it’s easy for everyone to contribute and ultimately help bring new therapies to patients.
Kelly Schick joined C4 Therapeutics in January 2021 as our Chief People Officer. Previously, Kelly served as AMAG Pharmaceuticals’ Senior Vice President, Chief Human Resources Officer and Head of Corporate Engagement. She joined AMAG in September 2016 and has 20 years of human resources experience in the pharmaceutical industry. Prior to AMAG, Kelly served as Head of Global Talent for Bristol-Myers Squibb (BMS) where she had responsibility for global talent management, talent acquisition, learning and development, organization effectiveness and diversity and inclusion for the company’s global manufacturing division. Before joining BMS in 2011, Kelly held a series of HR business partner roles of increasing responsibility supporting the research and development organization for Merck and Company, Inc. Kelly holds an M.A. in human resources and labor relations from the Curtis L. Carlson School of Management at the University of Minnesota and a B.A. in psychology from Boston University.
Transparency and collaboration are at the core of our success. Each day, we work together to find innovative ways to advance our science and bring transformative medicines closer to patients.
Mary Christian, Pharm.D., MBA joined C4 Therapeutics in July 2023 as our Senior Vice President, Regulatory. Previously, she served as Senior Vice President, Regulatory, Quality and Compliance at Lyndra Therapeutics. Mary has more than 20 years of regulatory and drug development experience across pharmaceutical and biotechnology companies. Prior to her role at Lyndra Therapeutics, Mary served as Vice President, Global Quality, Regulatory, Safety & Development Outsourcing at Cyclerion Therapeutics following her role as Vice President, Head of Global Regulatory Affairs at Ironwood Pharmaceuticals, where she built a full service, global regulatory strategy team that oversaw expansion of commercial asset indications, labels and pediatric development and led asset transitions across clinical development and regulatory approvals. Earlier in her career, Mary worked at Bristol-Myers Squibb in roles of increasing responsibility in regulatory and oncology strategic collaborations. She began her regulatory career at J&J Pharmaceutical Research & Development after more than 10 years serving patients in hospital and community pharmacy. She serves on the Scientific Advisory Boards of Promakhos Therapeutics and Syntis Bio. Mary holds an MBA from University of the Sciences in Philadelphia, a Doctor of Pharmacy from University of Florida and a B.S. in pharmacy from Rutgers College of Pharmacy.
What makes C4T special is our collaborative leadership environment that accelerates our ability to find solutions that advance our work while keeping the patients’ best interest at the center of everything we do.
Mayra Reyes-Armour, Ph.D. joined C4 Therapeutics in January 2021 and serves as our Senior Vice President, Technical Operations, Quality and Facilities. Previously, Mayra served as Biogen’s Head of Asset Development and Portfolio Management Operations. She joined Biogen in May 2012 and held a variety of roles with increasing responsibility in the Pharmaceutical Operations and Technology organization (PO&T), focusing on CMC strategy, supply, and lifecycle management. While at Biogen, Mayra led the successful operational launch of Biogen’s first rare disease drug, Spinraza®. Prior to Biogen, Mayra served as General Manager and Head of Development of Hovione, LLC (a subsidiary of Hovione FarmaCiencia SA). Mayra has more than 25 years of experience in process development and manufacturing of small molecules. Since 2018, she has served on the scientific advisory board of Element Therapeutics. Mayra holds a Ph.D. in physical organic chemistry from Cornell University and a B.S. in chemistry from the University of Puerto Rico.
I joined C4T to reach people and witness real progress made through applied science in areas of unmet need. The C4T team’s great talent, maturity and leadership drives our ability to create a platform with unbounded opportunities for impact.
Stew Fisher, Ph.D. is Senior Scientific Advisor to C4T. He has been with C4T since May 2016 and previously served as our Chief Scientific Officer. Prior to joining C4 Therapeutics, Stew held senior leadership roles at the Broad Institute, including Director of Quantitative Biochemistry and Enzymology, where he developed and implemented biochemical plans for therapeutic projects. He previously spent fifteen years at AstraZeneca in roles of increasing responsibility across target validation, drug discovery and clinical candidate support, including Executive Director of Infection Bioscience. Stew started his career at Hoffmann-La Roche as a Research Scientist after completing an NIH Post-Doctoral Fellowship at Harvard Medical School. Stew holds a Ph.D. in organic chemistry from the California Institute of Technology, and a B.A. in chemistry from the University of Vermont.
